Key facts
- It has raised $620K; the latest was Seed Round in Apr 2026.
- Notable investors include Innosphere Ventures, Colorado Venture Capital Authority.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Numiera Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Numiera Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Numiera Therapeutics
Developer of small-molecule drugs intended for oncology indications. The company develops mitochondrial-targeting small molecule drugs (vorasidenib, dordaviprone) for glioblastoma and other cancers through an IND-enabling dataset, orphan drug designation, supply chain, and clinical partnerships, enabling cancer patients to access more effective and targeted therapies for brain tumours and other difficult-to-treat malignancies.
- Sector
- Healthcare
- HQ
- Denver, CO, United States
- Founded
- 2023
- Employees
- 2
- Website
- numiera.com/
- Ownership
- Privately Held (backing)
Numiera Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Numiera Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Numiera Therapeutics in its N-PORT filings yet. We sweep new filings monthly.